CIK 0001228627
- Non-accelerated filer
- Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 113516358
- Phone
- +1 984-884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2012-06-18 | Kivel Richard Director | Grant or award · Stock Options (right-to-buy) | +20,000 | 20,000 | ||
| 2011-10-03 | Kivel Richard Director | Purchase | +2,500 | $1.04 | $3K | 2,500 |
| 2011-06-06 | Kivel Richard Director | Grant or award · Stock Options (right-to-buy) | +20,000 | 20,000 | ||
| 2010-09-17 | Kivel Richard Director | Grant or award · Stock Options (right-to-buy) | +20,000 | 20,000 |
Page 1 of 1 · 4 trades